11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients
- 888 Downloads
To evaluate, in prostate cancer (PCa) patients the potential of 11C-choline PET/CT as a guide to helical tomotherapy (HTT) of lymph-node (LN) relapses with simultaneous integrated boost (SIB). The efficacy and feasibility of HTT in terms of acute toxicity were assessed.
We enrolled 83 PCa patients (mean age 68 years, range 51 – 82 years) with biochemical recurrence after radical primary treatment (mean serum PSA 7.61 ng/ml, range 0.37 – 187.00 ng/ml; PSA0) who showed pathological findings on 11C-choline PET/CT only at the LN site. 11C-Choline PET/CT was performed for restaging and then for radiation treatment planning (PET/CT0). Of the 83 patients, 8 experienced further LN relapse, of whom 5 were retreated once and 3 were retreated twice (total 94 radiotherapy treatments). All pelvic and/or abdominal LNs positive on PET/CT0 were treated with high doses using SIB. Doses were in the range 36 – 74 Gy administered in 28 fractions. After the end of HTT (mean 83 days, range 16 – 365 days), serum PSA was measured in all patients (PSA1) and compared with PSA0 to evaluate early biochemical response. In 47 patients PET/CT was repeated (PET/CT1) to assess metabolic responses at the treated areas. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) were used to assess acute toxicity.
PET/CT0 revealed pathological LNs in the pelvis in 49 patients, pathological LNs in the abdomen in 15 patients pathological LNs in both the pelvis and abdomen in 18 patients, and pathological LNs in the pelvis or abdomen and other sites in 12 patients. All these sites were treated with HTT. With respect to PSA0, PSA1 (mean 6.28 ng/ml, range 0.00 – 220.46 ng/ml) showed a complete biochemical response after 66 of the 94 HTT treatments, a partial response after 12 treatments, stable disease after 1 treatment and progression of disease after 15 treatments. Of the 47 patients receiving PET/CT1, 20 showed a complete metabolic response at the treated area, 22 a partial metabolic response, 3 progression of disease and 2 stable disease. HTT with SIB was well tolerated in all patients. Grade 3 acute toxicity in the genitourinary tract was observed in two patients.
11C-Choline PET/CT is a valuable tool for planning and monitoring HTT in LN relapse after primary treatment. High-dose hypofractionated 11C-choline PET/CT-guided HTT with SIB is well tolerated and is associated with a high early biochemical response rate.
KeywordsCholine PET/CT Prostate cancer Lymph-node relapse HTT RT SIB
Conflicts of interest
- 2.Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer. 2004;100:1283–92. doi: 10.1002/cncr.20093.PubMedCrossRefGoogle Scholar
- 7.Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F, et al. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol. 2013;189:105–10. doi: 10.1016/j.juro.2012.09.001.PubMedCrossRefGoogle Scholar
- 8.Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43. doi: 10.1016/j.eururo.2011.07.060.PubMedCrossRefGoogle Scholar
- 10.Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2014;32:38.e9–16. doi: 10.1016/j.urolonc.2013.03.006.CrossRefGoogle Scholar
- 12.Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51–60. doi: 10.1016/j.eururo.2010.09.004.PubMedCrossRefGoogle Scholar
- 13.Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013;63:792–6. doi: 10.1016/j.eururo.2012.08.003.PubMedCrossRefGoogle Scholar
- 17.Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102:446–51. doi: 10.1111/j.1464-410X.2008.07592.x.PubMedCrossRefGoogle Scholar
- 19.Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889–97. doi: 10.1016/j.ijrobp.2010.11.031.PubMedCrossRefGoogle Scholar
- 23.Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14. doi: 10.1186/1748-717X-7-14.PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193–200. doi: 10.1016/j.radonc.2011.05.005.PubMedCrossRefGoogle Scholar
- 25.Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44. doi: 10.1186/1748-717X-6-44.PubMedCentralPubMedCrossRefGoogle Scholar
- 27.Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, et al. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol. 2011;187:479–84. doi: 10.1007/s00066-011-2249-z.PubMedCrossRefGoogle Scholar
- 35.Cozzarini C, Fiorino C, Di Muzio N, Alongi F, Broggi S, Cattaneo M, et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol. 2007;84:164–70. doi: 10.1016/j.radonc.2007.07.013.PubMedCrossRefGoogle Scholar
- 37.McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, et al. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013;85:e39–46. doi: 10.1016/j.ijrobp.2012.08.036.PubMedCrossRefGoogle Scholar
- 39.Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32–9. doi: 10.1111/j.1464-410X.2011.10422.x.PubMedCentralPubMedCrossRefGoogle Scholar
- 41.Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9. doi: 10.1016/j.eururo.2007.03.032.PubMedCrossRefGoogle Scholar
- 42.Suardi NG, Briganti A, Picchio M, Gallina A, Messa C, Gianolli L, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: validation by open pelvic-retroperitoneal lymphadenectomy. J Urol. 2009;181:829.CrossRefGoogle Scholar
- 43.Picchio M, Alongi F, Giovacchini G, Berardi G, Busnardo E, Crivellaro C, et al. 11C-Choline PET/CT image-guided tomotherapy treatment of lymph nodal relapse in prostate cancer patients. J Nucl Med. 2010;51:1274.Google Scholar
- 44.Picchio M, Alongi F, Giovacchini G, Di Rosa E, Cozzarini C, Landoni C, et al. 11C-Choline PET/CT image-guided radiotherapeutic treatment of lymph nodal recurrence in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2008;35:388.Google Scholar
- 46.Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74. doi: 10.1016/j.ijrobp.2006.04.029.PubMedCrossRefGoogle Scholar
- 47.Fiorino C, Alongi F, Perna L, Broggi S, Cattaneo GM, Cozzarini C, et al. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75:29–35. doi: 10.1016/j.ijrobp.2008.10.086.PubMedCrossRefGoogle Scholar